SEC Form 4 · accession 0001179110-17-013557

Allergan plc · AGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Legal Officer & Corp Sec

Period of report

Mar 29, 2017

Accepted (ET)

Oct 30, 2017 · 9:41 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001578845

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Shares, par value $0.001^F1,F5	Mar 29, 2017	L	2	$242.21	A	12,215	D
Ordinary Shares, par value $0.001^F2,F5	Jun 16, 2017	L	2	$235.96	A	17,651	D
Ordinary Shares, par value $0.0001^F3,F4,F5	Oct 26, 2017	M	7,988	—	A	25,639	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Performance Based Restricted Share Unit^F4	—	Oct 26, 2017	M	7,988	D	—	—	Ordinary Shares	7,988	0	D

F1Includes 2.1220 shares acquired on March 29, 2017 pursuant to a broker-assisted dividend reinvestment plan.
F2Includes shares reported on previously-filed Form 4s on April 4, 2017 and May 16, 2017, and includes 2.1850 shares acquired on June 16, 2017 pursuant to a broker-assisted dividend reinvestment plan.
F3The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019.
F4Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.
F5Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.